Stockreport

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com
PDF The 7 mg dose of OV329 demonstrated favorable safety and tolerability profile, reinforcing best-in-category potential for refractory epilepsies; Ovid advancing plans to [Read more]